Thermo Fisher Scientific Inc. (NYSE:TMO) Given Average Rating of "Moderate Buy" by Analysts

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) have received an average rating of "Moderate Buy" from the twenty research firms that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $604.05.

Several analysts have recently weighed in on TMO shares. Royal Bank Of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Citigroup reduced their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. UBS Group reduced their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Finally, The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.33% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. AG2R LA Mondiale Gestion D Actifs bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth $7,044,000. Swedbank AB boosted its stake in Thermo Fisher Scientific by 11.3% in the 1st quarter. Swedbank AB now owns 1,583,776 shares of the medical research company's stock worth $788,087,000 after purchasing an additional 160,621 shares during the period. Guinness Asset Management LTD boosted its stake in Thermo Fisher Scientific by 5.3% in the 1st quarter. Guinness Asset Management LTD now owns 75,551 shares of the medical research company's stock worth $37,596,000 after purchasing an additional 3,788 shares during the period. 1248 Management LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth about $173,000. Finally, Osterweis Capital Management Inc. boosted its stake in Thermo Fisher Scientific by 20.5% in the 1st quarter. Osterweis Capital Management Inc. now owns 77,455 shares of the medical research company's stock worth $38,542,000 after purchasing an additional 13,169 shares during the period. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $1.37 during trading on Thursday, hitting $412.02. 2,923,691 shares of the company's stock were exchanged, compared to its average volume of 1,955,503. The company has a market cap of $155.53 billion, a PE ratio of 24.17, a P/E/G ratio of 2.13 and a beta of 0.78. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The stock's 50 day moving average price is $410.39 and its two-hundred day moving average price is $485.33. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business's quarterly revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the business posted $5.11 earnings per share. Research analysts expect that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.